After a series of PI3k pileups, Genentech offloads a PhII-ready rival for firesale price
Why would Genentech, of all biopharma companies, out-license a PI3k inhibitor for only $5 million? That’s a question a few biotechs may be asking themselves this morning after seeing the terms in a deal between the biotech giant and little Australian biotech Novogen.
Genentech decided to offload GDC-0084 after completing a Phase I study of the drug for glioblastoma. Novogen ($NVGN) acknowledges that there have been several PI3k inhibitors in development, but says that this one is distinguished by its ability to cross the blood-brain barrier to reach the most common form of brain cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.